mRNA advances gain momentum as personalized cancer vaccine shows promise
Success in trials of a personalized mRNA melanoma vaccine from Moderna and Merck is reviving optimism for the technology beyond COVID-19.
A collaborative effort between Moderna and Merck has produced encouraging results for a patient-specific mRNA vaccine against melanoma, suggesting the technology can be repurposed for cancer treatment. Researchers highlight that the ability to program cells to produce virtually any protein underpins both the swift COVID-19 vaccine rollout and these newer therapies. The program benefited from early government funding through Operation Warp Speed, which President Trump praised as a major achievement.
Clinicians hope that successful cancer applications will help reduce lingering vaccine hesitancy, though they acknowledge it will not erase all concerns. The development marks a potential turning point for mRNA platforms, expanding their relevance beyond infectious diseases.
Why it matters
Proving mRNA can treat cancer could broaden its medical use and improve public perception of vaccines.
How this story developed
- Aug 19 Moderna shares soar as experimental melanoma vaccine shows promising results
- Aug 19 Moderna’s stock surged after the trial data were released.
- Aug 20 Interim Phase 3 data indicated the vaccine satisfied the primary endpoint of recurrence‑free survival and a key secondary endpoint of distant metastasis‑free survival.
- Aug 24 Moderna’s share price dropped more than 25% after an earlier surge following the trial announcement.
- Aug 28 Companies announced positive topline results from the ongoing phase‑3 trial of the personalized mRNA melanoma vaccine with Keytruda.
- Aug 31 The FDA approved Moderna’s mRNA influenza vaccine for adults 50 and older.
In this story
Related stories
4 in this thread